Abstract
The primary objective of this study was to compare the efficacy of a new internal teat sealant (ShutOutTM, Merck Animal Health, Madison, NJ) (SO) to the current U.S. industry leader (Orbeseal®, Zoetis, Parsippany, NJ) (ORB). This comparison was based on a non-inferiority evaluation of quarter-level new infection risk during the dry period, with secondary comparisons of cure risk, incidence of clinical mastitis at the cow level during the first 120 days in milk, as well as cow-level performance in early lactation based on milk production, somatic cell count (SCC), and risk for removal from the herd.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have